Back

Apolipoprotein B and the regression of lipidic plaque in statin-treated type 2 DM patients with coronary artery disease: the pre-specified sub-analysis from the OPTIMAL randomized controlled trial

30 August 2024 (10:00 - 10:50)
Organised by: Logo
Congress Presentation Part of: Lipids as risk factors for cardiovascular disease Lipids ESC Professional Premium Access ESC Congress 2024 European Society of Cardiology

About the speaker

Photo
Doctor Sayaka Funabashi

Kyorin University, Tokyo (Japan)

8 More presentations in this session

Presentation thumbnail
Physician disagreement with treatment guidelines as a critical barrier to achieving low-density lipoprotein cholesterol targets in very high-risk patients: an implementation science study
Associate Professor K. Cho (Gwangju, KR)
Abstract Slides Video
Presentation thumbnail
Lipoprotein(a) and atherosclerotic cardiovascular disease in a Brazilian tertiary hospital population
Doctor V. Zorzanelli Rocha (Sao Paulo, BR)
Abstract Slides Video
Presentation thumbnail
Impact of glucose metabolism status on the relationship between remnant cholesterol and ischemic risk after percutaneous coronary intervention: a large-scale long-term cohort study from real-world
Doctor K. Yan (Beijing, CN)
Abstract Slides Video
Presentation thumbnail
Association between lipoprotein particle concentration and size and progression of coronary plaque: the MACS Longitudinal Coronary CT angiography study
Doctor R. Quispe (Baltimore, US)
Abstract Slides Video
Presentation thumbnail
The association of inflammation, triglycerides and lipoprotein(a) with cardiovascular events in the UK Biobank
Doctor B. Tucker (Sydney, AU)
Abstract Slides Video

Access the full session

Session thumbnail
Lipids as risk factors for cardiovascular disease

The Event

Event poster

ESC Congress 2024

30 August 2024 10:00 CET
You may be interested in
thumbnail
Congress Presentation
Lowering apolipoprotein C-III associates with regression of lipidic plaque materials in type 2 DM patients with coronary artery disease: the pre-specified analysis from the OPTIMAL trial
thumbnail
Congress Presentation
Angioprotein-like 3 and atheroma progression in statin-treated type 2 diabetic patients with coronary artery disease: the pre-specified analysis from the OPTIMAL randomized controlled trial.
thumbnail
Congress Presentation
Different response of plaque regression under achieving LDL-C <1.8 mmol/L in non-obese and obese diabetic patients with coronary artery disease: a sub-analysis from the OPTIMAL randomized study

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources